We then treated ESCC cells with FAK inhibitors, including VS-6063 or VS-4718 (2.5 μM), and SFK inhibitors, such as ponatinib (5 μM) or dasatinib (0.5 μM), and observed that these inhibitors suppressed the expression of pACLY and pALDOA in ESCC cells. The gene discussed is PTK2; the disease is esophageal squamous cell carcinoma.